Bizrolertinib clinical trials
How each study uses bizrolertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the bizrolertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Who runs them
Industry 4 · Other 0
Hoffmann-La Roche (2) · Genentech, Inc. (1) · Suzhou Zanrong Pharma Limited (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test bizrolertinib.
Studies
Open first, then newest update. How each study uses bizrolertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveRecruitingPhase 2/3Hoffmann-La RocheNCT07413939Written as RO7771950
- A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid TumorsActive, not recruitingPhase 1/2Hoffmann-La RocheNCT05593094Written as ZN-A-1041
- A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy ParticipantsCompletedPhase 1Genentech, Inc.NCT07051993Written as ZN-A-1041
- Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid TumorsCompletedPhase 1Suzhou Zanrong Pharma LimitedNCT04487236Written as ZN-A-1041 50mg BID
Codes
What other systems call bizrolertinib · ClinicalTrials.gg INT018147
- UNII (FDA) UN8TM5120CBIZROLERTINIBOne source FDA
- NCI Thesaurus C215261BizrolertinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UN8TM5120C | BIZROLERTINIB | One source FDA |
| NCI Thesaurus | C215261 | Bizrolertinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.